ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,146.86
-0.21%
Dow Jones
38,589.16
-0.15%
Gold vs US Dollar
2,321.835
-0.48%
Brent Oil
81.95
-0.21%
Bitcoin
66,454.19
-0.28%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Alkermes PLC (ALKS)

  7. Alkermes PLC (ALKS) News

Alkermes (ALKS)

Alkermes PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ALKS
DateTimeSourceHeadlineSymbolCompany
11/06/202401:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
11/06/202401:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
04/06/202422:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
04/06/202422:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
04/06/202421:53Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
04/06/202421:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
04/06/202421:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
04/06/202421:45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
03/06/202412:00PR Newswire (US)Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024NASDAQ:ALKSAlkermes PLC
31/05/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALKSAlkermes PLC
29/05/202421:00PR Newswire (US)Alkermes to Participate in Two Upcoming Investor ConferencesNASDAQ:ALKSAlkermes PLC
29/05/202421:00PR Newswire (US)Alkermes to Participate in Two Upcoming Investor ConferencesNASDAQ:ALKSAlkermes PLC
28/05/202412:00PR Newswire (US)Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024NASDAQ:ALKSAlkermes PLC
28/05/202412:00PR Newswire (US)Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024NASDAQ:ALKSAlkermes PLC
14/05/202421:30Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ALKSAlkermes PLC
14/05/202412:00PR Newswire (US)Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific ConferencesNASDAQ:ALKSAlkermes PLC
14/05/202412:00PR Newswire (US)Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific ConferencesNASDAQ:ALKSAlkermes PLC
02/05/202412:00PR Newswire (US)Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo NordiskNASDAQ:ALKSAlkermes PLC
01/05/202412:00PR Newswire (US)Alkermes plc Reports First Quarter 2024 Financial ResultsNASDAQ:ALKSAlkermes PLC
24/04/202412:00PR Newswire (US)Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1NASDAQ:ALKSAlkermes PLC
17/04/202421:00PR Newswire (US)Alkermes to Report First Quarter Financial Results on May 1, 2024NASDAQ:ALKSAlkermes PLC
17/04/202421:00PR Newswire (US)Alkermes to Report First Quarter Financial Results on May 1, 2024NASDAQ:ALKSAlkermes PLC
09/04/202412:00PR Newswire (US)Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic HypersomniaNASDAQ:ALKSAlkermes PLC
09/04/202412:00PR Newswire (US)Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic HypersomniaNASDAQ:ALKSAlkermes PLC
08/04/202412:00PR Newswire (US)Alkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research SocietyNASDAQ:ALKSAlkermes PLC
07/03/202412:09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALKSAlkermes PLC
07/03/202412:00PR Newswire (US)Alkermes Announces Appointment of Nancy S. Lurker to Board of DirectorsNASDAQ:ALKSAlkermes PLC
27/02/202421:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
27/02/202421:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
27/02/202421:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALKSAlkermes PLC
 Showing the most relevant articles for your search:NASDAQ:ALKS

Your Recent History

LSE
OB89
Cred Ag Co 28
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved